[1] Keller ET, Brown J.  Prostate cancer bone metastases promote both osteolytic and osteoblastic activity[J]. J Cell Biochem, 2004, 91(4): 718-729.   doi: 10.1002/jcb.10662
[2] Reddi AH, Roodman D, Freeman C, et al.  Mechanisms of tumor metastasis to the bone: challenges and opportunities[J]. J Bone Miner Res, 2003, 18(2): 190-194.   doi: 10.1359/jbmr.2003.18.2.190
[3] Wang YP, Tao H, Yu XY, et al.  Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer[J]. Clin Lung Cancer, 2013, 14(3): 254-260.   doi: 10.1016/j.cllc.2012.09.001
[4] Yamada K, Yoshimura M, Kaise H, et al.  Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases[J]. Exp Ther Med, 2012, 3(2): 226-230.   doi: 10.3892/etm.2011.405
[5] 赵卫威, 解朋.  89Sr治疗前列腺癌骨转移的研究进展[J]. 中华男科学杂志, 2010, 16(3): 269-272.   doi: 10.13263/j.cnki.nja.2010.03.026
Zhao WW, Xie P.  Strontium-89 for bone metastases from prostate cancer: an update[J]. Nat J Androl, 2010, 16(3): 269-272.   doi: 10.13263/j.cnki.nja.2010.03.026
[6] Auclerc G, Antoine EC, Cajfinger F, et al.  Management of advanced prostate cancer[J]. Oncologist, 2000, 5(1): 36-44.   doi: 10.1634/theoncologist.5-1-36
[7] Lewington VJ.  Bone-seeking radionuclides for therapy[J]. J Nucl Med, 2005, 46(Suppl 1): S38-47.
[8] Marcus CS, Saeed S, Mlikotic A, et al.  Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP[J]. Clin Nucl Med, 2002, 27(6): 427-430.   doi: 10.1097/00003072-200206000-00008
[9] Russell RGG.  Bisphosphonates: the first 40 years[J]. Bone, 2011, 49(1): 2-19.   doi: 10.1016/j.bone.2011.04.022
[10] van Beek ER, Cohen LH, Leroy IM, et al.  Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates[J]. Bone, 2003, 33(5): 805-811.   doi: 10.1016/j.bone.2003.07.007
[11] Coleman RE.  Bisphosphonates in breast cancer[J]. Ann Oncol, 2005, 16(5): 687-695.   doi: 10.1093/annonc/mdi162
[12] Clézardin P, Ebetino FH, Fournier PGJ.  Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity[J]. Cancer Res, 2005, 65(12): 4971-4974.   doi: 10.1158/0008-5472.CAN-05-0264
[13] Aapro M, Abrahamsson PA, Body JJ, et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel[J]. Ann Oncol, 2008, 19(3): 420-432.   doi: 10.1093/annonc/mdm442
[14] Saad F, Sternberg CN.  Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy[J]. Nat Clin Pract Urol, 2007, 4(Suppl 1): S3-13.   doi: 10.1038/ncpuro0727
[15] James N, Pirrie S, Pope A, et al.  TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer[J]. Health Technol Assess, 2016, 20(53): 1-288.   doi: 10.3310/hta20530
[16] Powles T, Paterson S, Kanis JA, et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer[J]. J Clin Oncol, 2002, 20(15): 3219-3224.   doi: 10.1200/JCO.2002.11.080
[17] Saad F, Gleason DM, Murray R, et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer[J]. J Natl Cancer Inst, 2004, 96(11): 879-882.   doi: 10.1093/jnci/djh141
[18] Storto G, Klain M, Paone G, et al.  Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases[J]. Bone, 2006, 39(1): 35-41.   doi: 10.1016/j.bone.2005.12.004
[19] Lam MGEH, de Klerk JMH, van Rijk PP, et al.  Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases[J]. Anticancer Agents Med Chem, 2007, 7(4): 381-397.   doi: 10.2174/187152007781058596
[20] Choi JY.  Treatment of bone metastasis with bone-targeting radiopharmaceuticals[J]. Nucl Med Mol Imaging, 2018, 52(3): 200-207.   doi: 10.1007/s13139-017-0509-2
[21]

Harrison MR, Wong TZ, Armstrong AJ, et al. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease[J/OL]. Cancer Manag Res, 2013, 5: 1-14[2018-04-26]. https://www.ncbi.nlm.nih.gov/pubmed/23326203. DOI: 10.2147/CMAR.S25537.
[22] Parker CC, Coleman RE, Sartor O, et al.  Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial[J]. Eur Urol, 2018, 73(3): 427-435.   doi: 10.1016/j.eururo.2017.06.021
[23] Saad F, Carles J, Gillessen S, et al.  Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial[J]. Lancet Oncol, 2016, 17(9): 1306-1316.   doi: 10.1016/S1470-2045(16)30173-5
[24] 郭佳, 宋文忠.  89Sr、双膦酸盐及二者联合治疗肿瘤多发性骨转移的系统评价[J]. 实用临床医药杂志, 2017, 21(11): 54-58.
Guo J, Song WZ.  A systematic study of 89Sr, bisphosphonates and 89Sr plus bisphosphonates therapy for patients with bone metastases[J]. J Clin Med Pract, 2017, 21(11): 54-58.
[25] 李宁, 柴华, 杨志, 等.  唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效[J]. 国际放射医学核医学杂志, 2017, 41(4): 247-251.   doi: 10.3760/cma.j.issn.1673-4114.2017.04.003
Li N, Chai H, Yang Z, et al.  Clinical observation of zoledronic acid combined with 89Sr in the treatment of prostate cancer patients with bone metastases[J]. Int J Radiat Med Nucl Med, 2017, 41(4): 247-251.   doi: 10.3760/cma.j.issn.1673-4114.2017.04.003
[26] 白永利, 王林, 董莉.  唑来膦酸钠联合89SrCl2治疗骨转移瘤的临床疗效[J]. 现代肿瘤医学, 2016, 24(5): 815-818.   doi: 10.3969/j.issn.1672-4992.2016.05.039
Bai YL, Wang L, Dong L.  Clinical observation of zoledronic acid combined with 89SrCI2 in the treatment of bone metastasis tumor[J]. Med Oncol, 2016, 24(5): 815-818.   doi: 10.3969/j.issn.1672-4992.2016.05.039
[27] 李梅, 王火强.  89SrCl2联合伊班膦酸钠对肺癌骨转移骨痛的疗效分析[J]. 放射免疫学杂志, 2013, 26(4): 390-392.   doi: 10.3969/j.issn.1008-9810.2013.04.003
Li M, Wang HQ.  Therapeutic efficacy of 89SrCl2 combined with ibandronate in the treatment of osseous metastasis of lung cancer[J]. J Radioimmunol, 2013, 26(4): 390-392.   doi: 10.3969/j.issn.1008-9810.2013.04.003
[28] Lam MGEH, Dahmane A, Stevens WHM, et al.  Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases[J]. Eur J Nucl Med Mol Imaging, 2008, 35(4): 756-765.   doi: 10.1007/s00259-007-0659-z
[29] Waldert M, Klatte T, Remzi M, et al.  Is 153Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?[J]. World J Urol, 2012, 30(2): 233-237.   doi: 10.1007/s00345-011-0685-0
[30] Lam MGEH, de Klerk JMH, Zonnenberg BA.  Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined[J]. J Palliat Med, 2009, 12(7): 649-651.   doi: 10.1089/jpm.2009.9591
[31] Suominen MI, Rissanen JP, Käkönen R, et al.  Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis[J]. J Natl Cancer Inst, 2013, 105(12): 908-916.   doi: 10.1093/jnci/djt116
[32] Rasulova N, Lyubshin V, Arybzhanov D, et al.  Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease[J]. World J Nucl Med, 2013, 12(1): 14-18.   doi: 10.4103/1450-1147.113939